Deferral of MSMby Andrew I. Dayton, M.D., Ph. D.

• In November of 1998, FDA hosted a workshop on Donor Suitability.

• The highlights of this workshop were presented to the BPAC in December of 1998.

• Widespread adoption of NAT for HCV and HIV, providing, amongst other benefits, redundancy.

• Better understanding of blood bank error rates.

Previous slide

Next slide

Back to first slide

View graphic version